Company intelligence / Profile preview
Panacea Biotec
- Ownership
- Private
- Employees
- ~1146
- Development stage
- Commercial
Overview
Panacea Biotec has commercialized over 120 drugs including globally significant pediatric combination vaccines like EasyFive and EasySix. The company’s hexavalent vaccine EasySix was the world’s first fully liquid wP-based hexavalent vaccine protecting against six childhood diseases. It regained WHO prequalification after earlier quality issues were resolved. The company also has COVID-related candidates in its pipeline and recently expanded manufacturing capacity with international financing support for global supply through UN agencies.
- Therapeutic areas
- NephrologyEndocrinologyOtherOncologyInfectious Diseases
- Modalities
- Vaccinessmall moleculesmonoclonal antibodiesbiosimilarsnutraceuticals
- Industry
- Biotech
Drug pipeline
15 assets14 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Panacea Biotec.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Panacea Biotec.